Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease

Neuroscience Letters

Volumn 341, Issue 3, 2003, Pages 201-204

  Müller, Thomas ^a   Büttner, Thomas ^a   Gholipour, Ali Farshad ^a   Kuhn, Wilfried ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Coenzyme Q10; Parkinson's disease; Pharmacotherapy; Visual dysfunction

Indexed keywords

PLACEBO; UBIDECARENONE; DRUG DERIVATIVE; UBIQUINONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COENZYME; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL TEST; FEMALE; GOOD GENERAL CONDITION; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SUPPLEMENTATION; SYMPTOM; TASK PERFORMANCE; TREATMENT OUTCOME; VISION; ANALYSIS OF VARIANCE; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT;

AGED; ANALYSIS OF VARIANCE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; UBIQUINONE;

EID: 0037426566     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00185-X     Document Type: Article

References (24)

1. Büttner T., Kuhn W., Müller T., Patzold T., Heidbrink K., Przuntek H. Distorted color discrimination in 'de novo' parkinsonian patients. Neurology. 45:1995;386-387.
2. Chan A., Reichmann H., Kogel A., Beck A., Gold R. Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J. Neurol. 245:1998;681-685.
3. Feigin A., Kieburtz K., Como P., Hickey C., Claude K., Abwender D., Zimmerman C., Steinberg K., Shoulson I. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov. Disord. 11:1996;321-323.
4. Folkers K., Langsjoen P., Willis R., Richardson P., Xia L.J., Ye C.Q., Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proc. Natl. Acad. Sci. USA. 87:1990;8931-8934.
5. Fuente-Fernandez R., Phillips A.G., Zamburlini M., Sossi V., Calne D.B., Ruth T.J., Stoessl A.J. Dopamine release in human ventral striatum and expectation of reward. Behav. Brain Res. 136:2002;359-363.
6. Fuente-Fernandez R., Stoessl A.J. The biochemical bases for reward. Implications for the placebo effect. Eval. Health Prof. 25:2002;387-398.
7. Haas R.H., Nasirian F., Nakano K., Ward D., Pay M., Hill R., Shults C.W. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 37:1995;714-722.
8. Harnois C., Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest. Ophthalmol. Vis. Sci. 31:1990;2473-2475.
9. Harris J. Vision in Parkinson's disease: what are the deficits and what are their origins? Neuro-Ophthalmology. 19:1998;113-135.
10. Kinnear P.R. Proposals for scoring and assessing the 100-Hue test. Vis. Res. 10:1970;423-433.
11. Kuchle M., Brenner P.M., Engelhardt A., Naumann G.O. Ocular changes in MELAS syndrome. Klin. Monatsbl. Augenheilkd. 197:1990;258-264.
12. Kuhn W., Müller T., Winkel R., Danielczik S., Gerstner A., Hacker R., Mattern C., Przuntek H. Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. J. Neural Transm. 103:1996;1187-1193.
13. Matthews R.T., Yang L., Browne S., Baik M., Beal M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. USA. 95:1998;8892-8897.
14. Müller T., Kuhn W., Büttner T., Eising E., Coenen H., Haas M., Przuntek H. Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson's disease. J. Neurol. 245:1998;659-664.
15. Müller T., Kuhn W., Büttner T., Przuntek H. Distorted colour discrimination in Parkinson's disease is related to severity of the disease. Acta Neurol. Scand. 96:1997;293-296.
16. Müller T., Woitalla D., Peters S., Kohla K., Przuntek H. Progress of visual dysfunction in Parkinson's disease. Acta Neurol. Scand. 105:2002;256-260.
17. Overvad K., Diamant B., Holm L., Holmer G., Mortensen S.A., Stender S. Coenzyme Q10 in health and disease. Eur. J. Clin. Nutr. 53:1999;764-770.
18. Rotig A., Appelkvist E.L., Geromel V., Chretien D., Kadhom N., Edery P., Lebideau M., Dallner G., Munnich A., Ernster L., Rustin P. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet. 356:2000;391-395.
19. Schapira A.H., Mann V.M., Cooper J.M., Krige D., Jenner P.J., Marsden C.D. Mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol. 32:(Suppl.):1992;S116-S124.
20. Sharman E.H., Bondy S.C. Effects of age and dietary antioxidants on cerebral electron transport chain activity. Neurobiol. Aging. 22:2001;629-634.
21. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., Greenamyre J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22:2002;7006-7015.
22. Shults C.W., Haas R.H., Passov D., Beal M.F. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol. 42:1997;261-264.
23. Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., Juncos J.L., Nutt J., Shoulson I., Carter J., Kompoliti K., Perlmutter J.S., Reich S., Stern M., Watts R.L., Kurlan R., Molho E., Harrison M., Lew M. Effects of coenzyme q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59:2002;1541-1550.
24. Strijks E., Kremer H.P., Horstink M.W. Q10 therapy in patients with idiopathic Parkinson's disease. Mol. Aspects Med. 18:(Suppl.):1997;S237-S240.